Report cover image

Global Neurofibromatosis Type 2 Market - 2023-2030

Publisher DataM Intelligence 4Market Research LLP
Published Feb 09, 2024
Length 179 Pages
SKU # DTAM18531306

Description

Global Neurofibromatosis Type 2 Market - 2023-2030


Global Neurofibromatosis Type 2 Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors involving the central nervous system (CNS). Vestibular schwannomas are the tumors most frequently linked to neurofibromatosis type 2. The onset of neurofibromatosis type 2 symptoms can occur at any age, but they typically manifest in adolescence or the early twenties.

The NF2 gene codes for the production of the merlin protein. The neurological system, in especially the Schwann cells that encircle and insulate the nerve cells, or neurons, in the brain and spinal cord, produces this protein. As a tumor suppressor, merlin prevents cells from proliferating and dividing uncontrollably or too quickly.

Market Dynamics: Drivers & Restraints

Rise in research and developmental activities

Increasing focus on research and development and increasing demand for treatment options are expected to drive market growth. The increase in clinical studies is well supported by regulatory authorities which is expected to drive the growth of the neurofibromatosis Type 2 market growth.

The increasing genetic testing is also expected to increase the demand for the treatment of the disease as the side effects are minimal and the patient pool plays a major role in increasing the access to the available treatments. The development of targeted drugs like MEK inhibitors and TKIs, with encouraging clinical trial results increases the options for the patients suffering frm the disease. Thus, the above factors are expected to increase the market growth in the forecast period.

Restraint

Lack of drug approvals and fewer treatment options

Lack of drug approvals as well as limited treatment options in the market are expected to hinder the market growth. The absence of established, effective treatments creates uncertainty for patients, and healthcare providers are expected to reduce diagnostic procedures and also intervention in treatment procedures. The high cost of manufacturing drugs can also affect the market growth.

Segment Analysis

The global neurofibromatosis type 2 market is segmented based on tumor type, treatment type, end-user and region.

Surgery segment accounted for 49.8% of the market share

Surgery is considered to be the first line of treatment in most of the cases. Brain tumor surgery to remove the tumor is the usual course of treatment for the majority of brain tumors that arise with NF2. A craniotomy is a surgical technique where a neurosurgeon temporarily removes a part of the skull to access the tumor. An electrical device known as a hearing implant is surgically implanted as the first line of treatment.

Cochlear implants are one of the two types of hearing implants used in NF2. In most cases, surgery is still the primary course of treatment. Surgery is typically performed on patients who have lost all hearing or on those who have a tiny tumor where it is feasible to meaningfully try to preserve the nerve that provides hearing. Thus, the above factors are expected to hold the surgery segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the global neurofibromatosis type 2 market share

North America is expected to hold a dominant position in the market share during the forecast period due to the well-equipped health infrastructure, high-quality diagnostic procedures and equipment, and the increase in pharmaceutical production in the region.

The increase in the awareness among individuals of diagnostic procedures is also expected to drive market growth. An increase in awareness will increase early detection of the disease condition and proceed with the treatment options which increases the demand for the surgical as well as the drugs that are being allotted for the disease. Thus, the above factors are expected to drive the market growth in the region.

COVID-19 Impact Analysis

COVID-19 has affected the market growth unprecedently. There are many disruptions in healthcare access due to the lockdown and the supply chain has been disrupted among the borders of the country. The clinical trials of the drugs have been halted due to the shift of the company's interest in the production of COVID-19 drugs.

Market Segmentation

By Tumor Type
• Vestibular Schwannomas
• Meningiomas
• Other Tumors

By Treatment Type
• Surgery
Tumor Removal
Stereotactic Radiosurgery
Others
• Radiation Therapy
• Drug Therapy
Lapatinib
Selumetinib
Bevacizumab
Others
• Others

By End-User
• Hospitals
• Cancer Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The leading companies with a significant market share include Manus Aktteva Biopharma LLP, AstraZeneca Plc, OCEAN PHARMACEUTICAL, Vivace Therapeutics, Ikena Oncology, Inc., Recursion Pharmaceuticals Inc. among others

Why Purchase the Report?
• To visualize the global neurofibromatosis type 2 market segmentation based on tumor type, treatment type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of neurofibromatosis type 2 market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global neurofibromatosis type 2 market report would provide approximately 57 tables, 65 figures, and 179 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

179 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Tumor Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in research and developmental activities
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of drug approvals and fewer treatment options
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Epidemiology Statistics
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Russia-Ukraine War Impact Analysis
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. Tumor Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
7.1.2. Market Attractiveness Index, By Tumor Type
7.2. Vestibular Schwannomas
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Meningiomas
7.4. Other Tumors
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Surgery
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Tumor Removal
8.2.4. Stereotactic Radiosurgery
8.2.5. Others
8.3. Radiation Therapy
8.4. Drug Therapy
8.4.1. Lapatinib
8.4.2. Selumetinib
8.4.3. Bevacizumab
8.4.4. Others
8.5. Others
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Tumor Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Manus Aktteva Biopharma LLP*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AstraZeneca Plc
12.3. OCEAN PHARMACEUTICAL
12.4. Vivace Therapeutics
12.5. Ikena Oncology, Inc.
12.6. Recursion Pharmaceuticals Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us